Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects

R.J. Woodman; D.E. Celermajer; Peter Thompson; Joe Hung

doi:10.1042/CS20030296

Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects

R.J. Woodman, D.E. Celermajer, Peter Thompson, Joe Hung

Research output: Contribution to journal › Article

23 Citations (Scopus)

Abstract

Folic acid supplementation lowers total plasma homocysteine (tHcy) and improves endothelial function in individuals with coronary artery disease (CAD) and in those with additional CAD risk factors. In the present study, we assessed whether endothelial function is impaired in healthy subjects with hyperhomocysteinaemia but without other CAD risk factors and whether folic acid supplementation improves endothelial function in these subjects. Flow-mediated dilatation (FMD) of the brachial artery was performed on 26 healthy subjects, age 49±2 years (mean±S.E.M.), with high tHcy (15.6±1.5 mmol/l) and 16 healthy age-matched subjects with low tHcy (7.9±0.6 mmol/l; P

Original language	English
Pages (from-to)	353-358
Journal	Clinical Science
Volume	106
Issue number	4
DOIs	https://doi.org/10.1042/CS20030296
Publication status	Published - 2004

Fingerprint

Cite this

Woodman, R. J., Celermajer, D. E., Thompson, P., & Hung, J. (2004). Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects. Clinical Science, 106(4), 353-358. https://doi.org/10.1042/CS20030296

@article{fc1e57e55d384e9e8b67094bb727c5a5,

title = "Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects",

abstract = "Folic acid supplementation lowers total plasma homocysteine (tHcy) and improves endothelial function in individuals with coronary artery disease (CAD) and in those with additional CAD risk factors. In the present study, we assessed whether endothelial function is impaired in healthy subjects with hyperhomocysteinaemia but without other CAD risk factors and whether folic acid supplementation improves endothelial function in these subjects. Flow-mediated dilatation (FMD) of the brachial artery was performed on 26 healthy subjects, age 49±2 years (mean±S.E.M.), with high tHcy (15.6±1.5 mmol/l) and 16 healthy age-matched subjects with low tHcy (7.9±0.6 mmol/l; P",

author = "R.J. Woodman and D.E. Celermajer and Peter Thompson and Joe Hung",

year = "2004",

doi = "10.1042/CS20030296",

language = "English",

volume = "106",

pages = "353--358",

journal = "Clinical Science",

issn = "0143-5221",

publisher = "Portland Press Ltd.",

number = "4",

}

TY - JOUR

T1 - Folic acid does not improve endothelial function in healthy hyperhomocysteinaemic subjects

AU - Woodman, R.J.

AU - Celermajer, D.E.

AU - Thompson, Peter

AU - Hung, Joe

PY - 2004

Y1 - 2004

N2 - Folic acid supplementation lowers total plasma homocysteine (tHcy) and improves endothelial function in individuals with coronary artery disease (CAD) and in those with additional CAD risk factors. In the present study, we assessed whether endothelial function is impaired in healthy subjects with hyperhomocysteinaemia but without other CAD risk factors and whether folic acid supplementation improves endothelial function in these subjects. Flow-mediated dilatation (FMD) of the brachial artery was performed on 26 healthy subjects, age 49±2 years (mean±S.E.M.), with high tHcy (15.6±1.5 mmol/l) and 16 healthy age-matched subjects with low tHcy (7.9±0.6 mmol/l; P

AB - Folic acid supplementation lowers total plasma homocysteine (tHcy) and improves endothelial function in individuals with coronary artery disease (CAD) and in those with additional CAD risk factors. In the present study, we assessed whether endothelial function is impaired in healthy subjects with hyperhomocysteinaemia but without other CAD risk factors and whether folic acid supplementation improves endothelial function in these subjects. Flow-mediated dilatation (FMD) of the brachial artery was performed on 26 healthy subjects, age 49±2 years (mean±S.E.M.), with high tHcy (15.6±1.5 mmol/l) and 16 healthy age-matched subjects with low tHcy (7.9±0.6 mmol/l; P

U2 - 10.1042/CS20030296

DO - 10.1042/CS20030296

M3 - Article

C2 - 14641105

VL - 106

SP - 353

EP - 358

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 4

ER -

Access to Document

10.1042/CS20030296